In a major global healthcare milestone, the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS). This regulatory breakthrough marks the first approved immunotherapy for this indication in Europe, significantly expanding access to patients across 33 countries spanning four major regulatory jurisdictions — including the United States, United Kingdom, Kingdom of Saudi Arabia, and now the European Union.
This conditional authorization came after a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and reflects the urgent need for new treatment options in a patient population that previously faced limited alternatives. For those whose disease does not respond to traditional BCG therapy, radical cystectomy — the surgical removal of the bladder — was often the only remaining option, a procedure associated with significant impact on quality of life.
Clinical evidence from the Phase 2/3 QUILT-3.032 trial played a pivotal role in the decision, demonstrating a 71 % complete response rate, with many responses lasting up to 54 + months and a median duration of response of 26.6 months — results that underscored both efficacy and durability in a previously unmet medical niche. The trial also showed sustained cystectomy-free survival among responding patients at 12, 24, and 36 months.
By covering all 27 European Union member states plus Iceland, Norway, and Liechtenstein, this authorization broadens ANKTIVA’s footprint beyond its initial approvals, which included the U.S. Food and Drug Administration (FDA) in April 2024, the MHRA in the UK in July 2025, and the Saudi Food and Drug Authority in January 2026. Together, these authorizations make ANKTIVA one of the fastest-expanding immunotherapies for a specific bladder cancer indication, now authorized in a total of 33 countries within just under two years of its first regulatory milestone.
The approval strategy employed — conditional marketing authorization — reflects the EU’s commitment to providing early access to therapies that address serious diseases with high unmet needs, especially where traditional treatments have failed to produce meaningful results. Under this pathway, ongoing follow-up of patients and further safety and efficacy data will continue to be submitted to the EMA to support long-term outcomes and potentially secure full authorization in the future.
On the commercial and health system fronts, industry movement is now supporting rapid rollout. ImmunityBio has announced partnerships with regional distributors and established subsidiaries — such as a Dublin-based unit — to support European commercialization efforts and ensure that eligible adult NMIBC patients can access treatment as swiftly as possible under local pricing, reimbursement, and healthcare delivery frameworks. These strategic moves reflect broader efforts to integrate ANKTIVA into oncology care pathways across diverse healthcare markets in Europe.
The broader impact of this authorization extends beyond regulatory achievements. With bladder cancer among the top five most common cancers in the European Union, and approximately 150,000 local diagnoses annually, the availability of a first-of-its-kind immunotherapy option represents a turning point in patient care for those with BCG-unresponsive disease. The new treatment paradigm focuses on leveraging immune system activation — rather than surgery alone — with the potential to preserve bladder function and improve quality of life for many patients.
Investors have also taken notice of this regulatory momentum. Following the EC’s announcement, shares of ImmunityBio, Inc. saw significant rallies on global markets, reflecting investor confidence in the commercial potential of ANKTIVA’s expanded access, particularly as the biotech firm continues to pursue broader indications and additional regulatory submissions worldwide.
Looking ahead, ImmunityBio is actively working on further studies, including submissions for expanded indications and combination regimens in other tumor types, which could further extend ANKTIVA’s role in oncology treatment. For patients and clinicians alike, this European authorization marks a critical step forward — transforming a treatment landscape that has lacked effective solutions into one with a promising new immunotherapy at its core.